Use of methylene blue in the treatment of vasoplegic syndrome of post-operative heart surgery;Utilización de azul de metileno en el tratamiento del síndrome vasopléjico del postoperatorio de cirugía cardíaca

Medicina Intensiva

Volumn 30, Issue 6, 2006, Pages 293-296

  Mora Ordonez J M ^a,b   Sanchez Llorente F ^a   Galeas Lopez J L ^a   Hernandez Sierra B ^a   Prieto Palomino, M A ^a   Vera Almazan A ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Urbanización Pinos de Alhaurín   (Spain)

Author keywords

Cardiopulmonary bypass; Methylene blue; Shock; Vasoplegia

Indexed keywords

METHYLENE BLUE;

AGED; ARTICLE; CARDIOPULMONARY BYPASS; CASE REPORT; COST OF ILLNESS; FLUID THERAPY; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HEMODYNAMICS; HUMAN; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; SAFETY; SHOCK; SINGLE DRUG DOSE; SWAN GANZ CATHETER; VASCULAR DISEASE; VASOPLEGIA SYNDROME;

EID: 33748787163     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-5691(06)74527-2     Document Type: Article

References (13)

1. Leyh RG, Kofidis T, Struber M, Fischer S, Knobloch K, Wachsmann B, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Sur. 2003;125:1426-31.
2. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004;77:496-99.
3. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg. 2000; 15:347-53.
4. Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995;23:259-64.
5. Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B, et al. Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med. 2001;29:1860-7.
6. Peer G, Itzhakov E, Wollman Y, Chernihovsky T, Grosskopf I, Segev D, et al. Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant. 2001;16:1436-41.
7. Viaro F, Dalio M, Evora PR. Catastrophic cardiovascular adverse reactions to protamina are nitric oxide/cyclic guanosine monophosphate depent and endothelium mediated. Should methylene blue be the treatment of choice? Chest. 2002;123:1061-6.
8. Andrade JCS, Batista Filho ML, Evora PRB. Methylene blue administration in the treatment of vasoplegic syndrome after cardiac surgery. Rev Bras Circ Cardiovasc. 1996;11:107-14.
9. Drugdex® Editorial Staff. Drugdex® Information system. Micromedex INC. Englewood, Colorado (2004). Drug evaluation monograhs of methylene blue. Disponible en: http://mdxsefh. gpm.es
10. Johnson MR. Low systemic vascular resistance after cardiopulmonary bypass: Are we any closer to understanding the enigma? Crit Care Med. 1999;27:1048-50.
11. Gomes WJ, Carvalho AC, Palma JH, Teles CA, Branco JN, Silas MG, et al. Vasoplegic síndrome alter open herat surgery. J Cardiovasc Surg. 1998;39:619-23.
12. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment: an update. Eur J Cardiothorac Surg. 2002;21:232-44.
13. Dagenais F, Mathieu P. Rescue therapy with methylene blue in systemic inflammatory response syndrome after cardiac surgery. Can J Cardiol. 2003;19:167-9.